News
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.37% to 6,339.39 and Dow Jones Industrial Average DJIA falling 0.74% to 44,130.98.
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
22hon MSN
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...
Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...
Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback